SNPX News and Press, Synaptogenix Inc. From 02/23/22

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis Filing of protocol and Investigational New Drug Application expected in the first half of 2022; Clinical trial to follow PR Newswire NEW YORK , Feb...

Gainers: Biofrontera (NASDAQ:BFRI) +14%. Synaptogenix (NASDAQ:SNPX) +11%. IceCure Medical (NASDAQ:ICCM) +10%. Immunic (NASDAQ:IMUX) +10%. Oncternal Therapeutics (NASDAQ:ONCT) +10%. Losers: Sio Gene Therapies (NASDAQ:SIOX) -19%. Anavex Life Sciences (NASDAQ:A...

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients Scientific manuscript documenting evidence published in Journal of Alzheimer's Disease PR Newswire ...

SNPX did not achieve primary endpoints in two Phase 2 studies for Bryostatin for the treatment of Alzheimer’s Disease in moderately severe to severe patients. Post-hoc analysis of 95 patients from these two studies with MMSE 10-15, and not taking Namenda, revealed a statistical...

Gainers: Elite Education Group International (NASDAQ:EEIQ) +40%. Bit Digital (NASDAQ:BTBT) +21%. Zeta Global Holdings (NYSE:ZETA) +19%. Synaptogenix (NASDAQ:SNPX) +18%. Marine Petroleum Trust (NASDAQ:MARPS) +16%. Navios Maritime (NYSE:NM) +15%. Biomerica (NASDAQ:BMRA) +13%. Unico Am...

Gainers: Aditxt (NASDAQ:ADTX) +22%, Synaptogenix (NASDAQ:SNPX) +17%, Shineco (NASDAQ:TYHT) +13%, SmileDirectClub (NASDAQ:SDC) +12%, Silverback Therapeutics (NASDAQ:SBTX) +9%. Losers: UpHealth (NYSE:UPH) -34%, Unity Biotechnology (NASDAQ:UBX)&#...

Futures are up over 0.4% in the pre-market sessions and it looks like it will be a bull’s day today. Futures on the Dow Jones Industrial Average gained 151 points, or 0.47%. S&P 500 futures rose 0.44% while Nasdaq 100 futures added 0.4%. Treasury Secretary Janet Yellen cautioned Tu...

Synaptogenix Announces Participation at the Benzinga Healthcare Small Cap Conference PR Newswire NEW YORK , Sept. 28, 2021 /PRNewswire/ -- Synaptogenix, Inc (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurod...

Few stocks with a market cap above a billion dollars display as much volatility as Cassava Sciences. Their efforts to develop a drug for Alzheimer's patients have recently been met with attacks by short-sellers alleging fraud. There are numerous ways for investors to position them...

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire NEW YORK , Sept. 10, 2021 /PRNewswire/ -- Synaptogenix, Inc (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics...